Rybelsus, a once-daily oral medication, represents a significant advancement in diabetes treatment, particularly for those managing Type 2 diabetes. It contains semaglutide, a GLP-1 receptor agonist that targets multiple aspects of glucose regulation. By stimulating insulin release and inhibiting glucagon, Rybelsus plays a critical role in lowering blood sugar levels…